### Bloodspot programme delivery and expansion: Complexities from a Laboratory Perspective

Dr Jennifer Brady Consultant Clinical Biochemist The Newborn Bloodspot Screening Laboratory



NHCP conference 27<sup>th</sup> March 2025

#### CHI | Connolly | Crumlin | Tallaght | Temple Street 🛛 🛞 ம 存 💿

new children's hospita

Connolly

CRA Registered Charity Number (RCN): 20202295. Revenue Charitable Status CHY: 22235 | www.childrenshealthireland.ie

### **Role in the Newborn Screening Laboratory**

- Ensure appropriate clinical pathways are followed for suspected cases
- Ensure QMS issues are resolved
- Planning and sign of new laboratory processes/methods









### **Newborn Bloodspot Screening**


Aim: **Early detection** of rare inherited metabolic, hormonal or functional disorders before the onset of any clinical manifestations, enabling the **early introduction of treatment** which will lead to a better clinical outcome, avoid significant morbidity or premature mortality





### Screening programme: pathway from sample to result & follow up


#### **Pre-analytical**



#### Analytical



Post analytical



**KPIs** 

### **Conditions screened for in the Republic of Ireland**

- 1966 Phenylketonuria (PKU)
- 1971 Homocystinuria (HCU)
- 1972 Maple Syrup Urine Disease (MSUD)
  - Classical Galactosaemia
- 1979 Congenital Hypothyroidism (CHT)
- 2011 Cystic Fibrosis (CF)
- 2018 Medium Chain acyl CoA Dehydrogenase Deficiency (MCADD)
  - Glutaric Aciduria Type 1 (GA1)
- 2022 Adenosine Deaminase deficiency Severe Combined Immunodeficiency (ADA-SCID)

SMA and SCID approved for addition to the programme

### **Process for adding conditions to the programme**



### **Programme expansion workstreams**




#### Clinical

- Contact pathway
- Clinical examination
- Diagnostic pathway
- Referral pathway

#### Communication

- PHNs/Midwives
- Paediatricians
- Parent information
- Practical guide
- HSE website
- HSELand elearning





# Laboratory aspects of expansion

- Precision
- Accuracy
- Carryover
- Limit of quantitation

#### Determination of cut-off value

- Analysis of 5000 'not affected' cards (good quality)
- Verification of preliminary cut-off with known positive cases
- o Review of cut-offs of other laboratories, literature and international databases
- Consider factors such as gestational age, birth weight
- Further analysis to estimate false positive rate

Compliance with ISO15189:2022 Medical laboratories – requirements for quality and competence

# **Ongoing Quality Assurance**

- KPIs agreed with NNBSP governance group
- Time to clinical pathway
- False positive rates


Within laboratory

- Ongoing review of cut-offs
- Internal QC
- Participation in external quality assessment schemes/inter-laboratory comparisons

### Addition of SMA and SCID to NBS programme

- Spinal Muscular Atrophy (SMA) is a rare neuromuscular condition associated with irreversible neuron loss
- Caused by homozygous deletions in the SMN1 gene (95% of cases)
- NBS is based on detection of this homozygous deletion in the DBS
- The number of SMN2 copy number determines disease severity (2<sup>nd</sup> line testing)
- Estimated incidence of childhood presentations (types 1-3) in Ireland 1:14,653<sup>1</sup>
- The availability of disease modifying treatments has improved the prognosis especially when instituted early

### NBS for SCID using TREC (T cell receptor excision circle) assay



# **Multiplex RT-PCR for SCID/SMA NBS**

EONIS™ assay consists of four easy steps; punching, extraction, amplification and data analysis.

Dedicated analysis software enables quantification of TREC and KREC, while SMN1 results are reported qualitatively. SMA carrier status will not be detected or reported. RPP30 is used as an internal amplification control as well as basis for the quantification. Software analysis includes automated run acceptance criteria from kit controls to ensure that the quality of measured data is not compromised.



Punching of DBS samples and controls

14	a l
	Ď

Extraction with manual or automated workflow



Amplification of TREC, KREC, SMN1 & RPP30



Result interpretation in the EONIS<sup>™</sup> analysis software



Amplification curves

PUNCHING

EXTRACTION


AMPLIFICATION

DATA ANALYSIS

### **Molecular Technology: Change Management**

- New equipment
- Staff expertise and training on new equipment
- Dedicated laboratory space
- Processes to avoid risk of contamination
- new workflows
- separate workspaces for bloodspot punching and PCR analysis
- > new 'culture' for staff working in this area

### **Timelines of Expansion**



# Questions





CHI | Connolly | Crumlin | Tallaght | Temple Street 🛞 🗓 🕞 🎯 CRA Registered Charity Number (RCN): 20202295. Revenue Charitable Status CHY: 22235 | www.childrenshealthireland.ie